Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $23 price target.
June 12, 2023 | 3:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals and maintained a $23 price target.
The reiteration of the Buy rating and maintenance of the $23 price target by Needham analyst Joseph Stringer indicates a positive outlook for Phathom Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100